Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors

The identification of T790M as acquired resistance mechanism was clinically feasible. Although T790M had no prognostic or predictive role in the present study, further research is necessary to identify patients with T790M-mutant tumors who might benefit from newly developed T790M-specific TKIs.